Calabria-AstraZeneca Tumor Protocol
- REGGIO CALABRIA, italy (April 8, 2025) – A technical meeting focused on oncology, prevention, and research, promoted by the Office of the Health Guarantor of the Calabria region,...
- A collaboration agreement has been initiated between AstraZeneca Italia and the regional health guarantor, Anna maria Stanganelli, to jointly develop more innovative healthcare pathways.
- AstraZeneca's delegation, led by Country President and Managing Director Claudio Longo, was welcomed by Domenico Giannetta, President of the Special Supervisory Commission of the Regional Council, who conveyed...
AstraZeneca and Calabria Region Collaborate on Oncology, Prevention, and Research
Table of Contents
REGGIO CALABRIA, italy (April 8, 2025) – A technical meeting focused on oncology, prevention, and research, promoted by the Office of the Health Guarantor of the Calabria region, was recently held at the “Mattia Preti” cultural center. Discussions centered on prevention strategies,oncological and chronic disease research,and safeguarding vulnerable populations. Participants also reviewed the latest advancements in oncological patient care, especially concerning the implementation of therapeutic welfare diagnostic pathways.
Strategic Collaboration for Innovative Healthcare
A collaboration agreement has been initiated between AstraZeneca Italia and the regional health guarantor, Anna maria Stanganelli, to jointly develop more innovative healthcare pathways. the aim is to enhance prevention activities and leverage digital solutions, ultimately ensuring equitable, rapid, and enduring access to health services for citizens.
AstraZeneca’s delegation, led by Country President and Managing Director Claudio Longo, was welcomed by Domenico Giannetta, President of the Special Supervisory Commission of the Regional Council, who conveyed greetings from Prime Minister Filippo Mancuso. The meeting included key figures such as Gianfranco Filippelli, coordinator of the Calabrian oncological network; Vincenzo Adamo, coordinator of the Sicilian oncological network; and Tommaso Calabrò, General Manager of the Health Protection Department of the Calabria Region. Discussions focused on integrated and innovative solutions to address the population’s healthcare needs.
Statements from Leadership
The collaboration with the Guarantor for the Health of the Calabria Region represents a valuable opportunity to contribute to strengthening the ecosystem. We believe that our experience in research and digital solutions can be beneficial to institutions in developing increasingly effective, integrated, and sustainable care pathways. This protocol enables us to work closely with the territory, enhancing our understanding of patient needs and making us more effective in contributing to the definition of innovative models that concretely address health priorities within the regional context.
— Claudio Longo, President, AstraZeneca Italia
The continuous and rapid conversion of knowledge on health issues, the new expectations of citizens and patients, and the challenges faced by institutions regarding sustainability and reducing inequalities in access to care are key themes that research and innovation must address. Through this protocol, we aim to enhance a collaboration that stems from mutual understanding and the identification of common objectives.
— Francesca Patarnello, Vice President, AstraZeneca Italia
Today marks the begining of a virtuous path, an critically important addition to the collaborations already formalized in recent months and those currently being defined with other significant entities on the national stage. Our primary objective is to promote preventive initiatives among Calabrian citizens, including screening campaigns for the most vulnerable, while emphasizing the importance of institutional synergy with those working within the health system. I thank President longo for the esteem shown to the guarantee body that I represent, and I hope that the joint working group can operate effectively to reduce inequalities in access to care for Calabrian citizens. ‘Close the care gap’ – that is our goal.
— Anna Maria Stanganelli, Regional Health Guarantor
Joint Working Group to Drive Innovation
The initial phase of this collaboration involves establishing a joint working group comprised of representatives from the Guarantor of Health of the Calabria Region and AstraZeneca.This group will be responsible for identifying and developing tangible projects aimed at innovating regional healthcare and optimizing assistance pathways. This memorandum of understanding aligns with AstraZeneca’s broader strategy of building collaborations with Italian regions, following similar agreements signed in recent years with Emilia-Romagna and Friuli-Venezia Giulia.
Additional Details
Further details regarding specific projects and initiatives resulting from this collaboration will be released as they become available.
AstraZeneca and Calabria Region: A Q&A on Healthcare Collaboration
Introduction:
This article delves into a significant collaboration between AstraZeneca Italia and the Calabria region of Italy. We’ll explore the key aspects of this partnership, focusing on its goals, potential impact, and the individuals driving it forward. This information is based solely on the provided content.
Q: what is the core focus of the collaboration between AstraZeneca Italia and the Calabria Region?
A: The collaboration centers on improving healthcare, with a particular emphasis on oncology, prevention, and research. This includes enhancing prevention activities, supporting oncological and chronic disease research, and leveraging digital solutions too improve healthcare pathways. The partnership aims to ensure equitable, rapid, and enduring access to health services for the citizens of calabria.
Q: Where and when did this collaboration begin?
A: The foundation for this collaboration was laid at a technical meeting held at the “Mattia Preti” cultural center in Reggio Calabria, italy, on April 8, 2025. The meeting was promoted by the Office of the Health Guarantor of the Calabria region.
Q: Who are the key players involved in this partnership?
A: The primary entities involved are:
AstraZeneca Italia: Represented by Country President and Managing Director Claudio Longo and Vice President Francesca Patarnello.
The Calabria Region: Specifically, the Regional Health Guarantor, Anna Maria Stanganelli, plays a crucial role. Other key figures include Domenico Giannetta (President of the Special Supervisory Commission of the Regional Council), Gianfranco filippelli (coordinator of the calabrian oncological network), Vincenzo Adamo (coordinator of the sicilian oncological network), and Tommaso Calabrò (General Manager of the Health Protection department of the Calabria Region).
Q: What specific areas of healthcare will this collaboration address?
A: The partnership is designed to impact multiple areas:
Oncology: focusing on advancements in oncological patient care, including the implementation of therapeutic welfare diagnostic pathways.
Prevention: Promoting preventive initiatives and screening campaigns.
Research: Supporting research into oncological and chronic diseases.
Digital Solutions: Leveraging digital tools to improve access to healthcare.
Q: What do key leaders say about the importance of this collaboration?
A:
Claudio Longo, President, AstraZeneca italia: Emphasizes the value of contributing to strengthening the healthcare ecosystem by leveraging experience in research and digital solutions to create effective, integrated, and enduring care pathways. He highlights the goal of understanding patient needs and developing innovative models tailored to the regional context.
Francesca Patarnello,Vice President,AstraZeneca Italia: Highlights the importance of addressing critical healthcare issues. She aims to enhance collaboration rooted in mutual understanding and common objectives.
Anna Maria Stanganelli, Regional health Guarantor: Views this as the start of a valuable endeavor and expresses her intention to reduce healthcare inequalities in access to care for Calabrian citizens.
Q: What is the role of the Joint Working Group?
A: The initial phase involves establishing a Joint Working Group comprising both AstraZeneca and regional representatives. This group will identify and develop specific projects aimed at innovating regional healthcare and optimizing assistance pathways.
Q: Where does this collaboration fit within AstraZeneca’s broader strategy?
A: This agreement aligns with AstraZeneca’s strategy of building collaborations with various Italian regions, with similar agreements formed with Emilia-Romagna and Friuli-Venezia Giulia in recent years.
Q: What are the expected outcomes of this collaboration?
A: The partnership aims to:
Improve healthcare access for citizens.
Enhance prevention initiatives.
Advance oncology and chronic disease research.
Leverage digital solutions in healthcare.
Identify and develop tangible projects in the regional healthcare sector.
Q: Where can I find additional details about specific projects and initiatives?
A: Further details regarding specific projects and initiatives will be released as they become available.